There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ENDRA Life Sciences Inc (NDRA) and Denali Therapeutics Inc (DNLI) with bullish sentiments.
ENDRA Life Sciences Inc (NDRA)
In a report released today, Vernon Bernardino from H.C. Wainwright initiated coverage with a Buy rating on ENDRA Life Sciences Inc and a price target of $6. The company’s shares closed on Friday at $1.51, close to its 52-week low of $0.90.
Bernardino commented:
“Our $6 PT was derived by using a 19.6% weighted-average cost of capital for ENDRA shares to discount free cash flows from annual sales of TAEUS, the company’s next-generation imaging technology platform, dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 0% terminal growth rate and 78% clinical program probability of success, which is in line with approval rates observed, 2013-2016, for Class II devices prior to 510(k) regulatory submission.”
According to TipRanks.com, Bernardino has 0 stars on 0-5 star ranking scale with an average return of -7.0% and a 28.6% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Innovus Pharmaceuticals Inc, Jaguar Animal Health, and Can-Fite BioPharma.
ENDRA Life Sciences Inc has an analyst consensus of Strong Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
Denali Therapeutics Inc (DNLI)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Denali Therapeutics Inc, with a price target of $28. The company’s shares closed on Friday at $20.01.
Fein noted:
“We include in our valuation given their clinical stage, and view DNL310 as a free call option at this point. Our 12-month price target of $28/share is based on an equally weighted composite of (a) $25/share, as a 35x multiple of taxed and diluted FY34 GAAP EPS of $7.66 discounted back to and (b) an NPV of $30/share (discount rate 12.0%, growth rate 2.5%).”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.6% and a 41.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Denali Therapeutics Inc with a $28 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
